MI-503 NEW
| Price | $117 | $219 | $366 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-11 |
Product Details
| Product Name: MI-503 | CAS No.: 1857417-13-0 |
| Purity: 99.99% | Supply Ability: 10g |
| Release date: 2024/11/11 |
Product Introduction
Bioactivity
| 名稱 | MI-503 |
| 描述 | MI-503 is an efficient and selective Menin-MLL inhibitor with an IC50 of 14.7 nM. In human MLL leukemia cell lines, MI-503 has a significant growth inhibition effect (GI = 250 nM-570 nM). |
| 細(xì)胞實(shí)驗(yàn) | Leukemia cells are treated with MI-503 or 0.25% DMSO and cultured at 37 °C for 7 days. Media is changed on day 4, viable cell numbers are restored to the original concentration and MI-503 are re-supplied. MTT cell proliferation assay kit is then employed, and plates are read for absorbance at 570 nm using a microplate reader. |
| 動(dòng)物實(shí)驗(yàn) | For efficacy studies in MV4;11 subcutaneous xenograft mice model, 5×10^6 cells are injected into the 4-6 week old female BALB/c nude mice. Treatment is started when the tumor size reached ~100 mm^3. Vehicle (25% DMSO, 25% PEG400, 50% PBS) or compounds (MI-463 or MI-503) are administrated once daily at designated doses using i.p. injections. |
| 體外活性 | Treatment of murine bone marrow cells (BMC) transformed with the mLL-AF9 oncogene with MI-503 results in substantial growth inhibition (GI50: 0.22 μM). The cell growth inhibitory effect of MI-503 is time-dependent, with a pronounced effect achieved after 7-10 days of treatment. |
| 體內(nèi)活性 | Following a single intravenous or oral administration, MI-503 rapidly attains high concentrations in peripheral blood and demonstrates significant oral bioavailability (75%). This compound effectively suppresses tumor growth through daily intraperitoneal (i.p.) doses, leading to an over 80% decrease in MV4;11 tumor volume, including complete regression in two mice. Continuous treatment over ten days notably delays the progression of mLL leukemia and substantially lowers the leukemia tumor burden in mice. Additionally, combined use of MI-503 and MI-463 significantly diminishes the expression of Hoxa9 and Meis1, indicating a potent antitumor activity. |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 45 mg/mL (79.7 mM), Sonication is recommended. H2O : Insoluble |
| 關(guān)鍵字 | Inhibitor | inhibit | MI 503 | MI503 | Epigenetic Reader Domain | MI-503 |
| 相關(guān)產(chǎn)品 | ABBV-744 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | Tazemetostat | Piribedil | GSK126 | Curcumin | EPZ015666 | dBET6 | Naphthol AS-E | MRTX-1719 | Bisdemethoxycurcumin |
| 相關(guān)庫(kù) | 組蛋白修飾化合物庫(kù) | 經(jīng)典已知活性庫(kù) | 表觀遺傳庫(kù) | 染色質(zhì)修飾分子庫(kù) | 抑制劑庫(kù) | 干細(xì)胞分化化合物庫(kù) | PPI抑制劑庫(kù) | 口服活性化合物庫(kù) | 已知活性化合物庫(kù) | 共價(jià)抑制劑庫(kù) |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2780.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $47.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $20.00/25Kg/Drum |
Wuhan Mulei New Material Technology Co. Ltd
|
2021-04-02 | ||
| $0.00/1mg |
VIP1Y
|
Hubei Chuchang Biotech Co., Ltd.
|
2024-03-28 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY